A5065098475- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Gastric Cancer Management and Outcomes
- Palliative Care and End-of-Life Issues
- Neuroendocrine Tumor Research Advances
- Multiple and Secondary Primary Cancers
- Cancer survivorship and care
- PI3K/AKT/mTOR signaling in cancer
- Neutropenia and Cancer Infections
- Neuroblastoma Research and Treatments
- Cancer therapeutics and mechanisms
- Anesthesia and Sedative Agents
- Pain Management and Opioid Use
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Childhood Cancer Survivors' Quality of Life
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Occupational and environmental lung diseases
- Pleural and Pulmonary Diseases
- Pain Management and Placebo Effect
- Respiratory Support and Mechanisms
- Cancer, Stress, Anesthesia, and Immune Response
Hôpital Intercommunal de Créteil
2015-2025
Hôpital Larrey
2021
Université Paris-Est Créteil
2017-2018
Hôpital Saint-Antoine
2007-2015
Sorbonne Université
2007-2015
Assistance Publique – Hôpitaux de Paris
2012-2015
Hôpital Tenon
2014
Inserm
2012
Hôpital Paris Saint-Joseph
2012
Immune checkpoint inhibitors (ICI) have revolutionized the management of cancer. They can induce immune-related adverse events (irAE) leading to intensive care unit (ICU) admission. We aimed describe irAEs for ICU admissions in solid cancer patients treated with ICIs.This prospective multicenter study was conducted France and Belgium. Adult tumor systemic ICIs within last 6 months, requiring non-programmed admission were included. Patients admitted microbiologically documented sepsis...
In an open-label multicenter non-randomized non-comparative phase II study in patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC), oncogenic addiction (EGFR mutation or ALK/ROS1 fusion), disease progression after tyrosine-kinase inhibitor and no prior chemotherapy (NCT04042558), atezolizumab, carboplatin, pemetrexed without bevacizumab showed some promising result. Beyond the clinical evaluation, we assessed safety patient-reported outcomes (PROs) to provide...
Based on improvements in recurrence-free and overall survival, osimertinib is now widely used as an adjuvant treatment stage II-IIIA non-small cell lung cancer (NSCLC) presenting with a common epithelial growth factor receptor (EGFR) mutation. Histological transformation well-known resistance mechanism to EGFR-mutated metastatic NSCLC, but we currently have insufficient data recurrence mechanisms the context. We present here case of patient treated small (SCLC) recurrence. A 54-year-old man,...
ROS1 chromosomic rearrangement is a rare oncogenic driver, and patients with this benefit from specific targeted treatments in the first-line setting. However, therapeutic options are limited pretreated patients. Brigatinib validated drug for ALK rearrangements, also has an vitro activity against ROS1. In vivo efficacy suggested some clinical series. We aimed to specifically study brigatinib advanced non-small-cell lung cancer (NSCLC). retrospectively collected data 20 centers France. was...
Use of immune checkpoint inhibitors (ICIs) is associated with new response types, such as hyperprogressive disease (HPD), whose definition still being discussed. Some authors use dynamic indexes to define HPD. However, since the Checkmate-743 study, ICIs have been a first-line therapy for pleural mesothelioma (PM), thereby making less appropriate. The aim this study describe two cases HPD and then discuss its definitions implications.
Brigatinib is a next-generation ALK inhibitor (ALKi) that shows efficacy in naïve and post-crizotinib ALK+ advanced NSCLCs (aNSCLCs). The of brigatinib was retrospectively assessed patients with aNSCLCs included the French Early-Access Program (1 August 2016−21 January 2019). primary endpoint investigator-assessed progression-free survival (invPFS) analysis updated 2021 longer follow-up, focused on post-brigatinib lorlatinib efficacy. Sixty-six centers 183 patients: median age 60 ± 12.7...
9045 Background: Brigatinib is a next-generation ALK inhibitor initially developed in pre-treated ALK+ NSCLC. Data on the efficacy of brigatinib real world remain rare. Methods: This retrospective multicentric study analyzed ALK-+ advanced NSCLC patients pretreated with at least two tyrosine-kinase inhibitors, including crizotinib, and enrolled French early access program. The primary endpoint was investigator-assessed progression-free survival (PFS). Results: 104 were included (mean age,...